Standard BioTools (STU:FLB) EPS (Basic): €0.17 (TTM As of Mar. 2026)


STU:FLB Standard BioTools Inc STU:FLB
31 GF Score
Price €0.69
GF Value €0.46
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools EPS (Basic)?

Standard BioTools STU:FLB +2.22% 31 EPS (Basic) is €0.17 as of Mar. 2026. GuruFocus rates STU:FLB with a GF Score™ of 31/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Standard BioTools's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.17.

Standard BioTools's EPS (Diluted) for the three months ended in Mar. 2026 was €0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.17.

Standard BioTools's EPS without NRI for the three months ended in Mar. 2026 was €-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.08.

During the past 3 years, the average EPS without NRI Growth Rate was 50.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Standard BioTools's highest 3-Year average EPS without NRI Growth Rate was 63.60% per year. The lowest was -66.50% per year. And the median was 15.10% per year.

Standard BioTools  (STU:FLB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Standard BioTools EPS (Basic) Related Terms

Standard BioTools EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Standard BioTools's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools EPS (Basic) Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -2.29 -0.86 -0.50 -0.17

Standard BioTools Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.08 -0.08 0.04 0.29
STU:FLB
31GF Score
Standard BioTools Inc STU:FLB
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Standard BioTools's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-63.961-0)/381.623
=-0.17

Standard BioTools's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(109.914-0)/388.202
=0.28

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.17 mean?
Standard BioTools (STU:FLB) has a EPS (Basic) of €0.17 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' EPS (Basic) too high?
Standard BioTools' current EPS (Basic) is €0.17. Overall, Standard BioTools has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' EPS (Basic) compare to CATX and KIDS?
Standard BioTools' EPS (Basic) of €0.17 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Standard BioTools and its competitors. Standard BioTools's current EPS (Basic) is €0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.69 — trading 50% above its estimated fair value. The current EPS (Basic) is €0.17. Standard BioTools' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current EPS (Basic) is €0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.69 is trading 50% above its estimated GF Value™ of €0.46. GuruFocus considers Standard BioTools to be Significantly Overvalued.

Key valuation signals for STU:FLB:

  • EPS (Basic): €0.17
  • GF Value™: €0.46 vs. price of €0.69 (50% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
31GF Score

Get the complete analysis for STU:FLB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.46
GF Value